Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04915508 · ClinicalTrials.gov registry record · Phase 2
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
A Phase 2 study of Prostate Adenocarcinoma and Stage IVB Prostate Cancer AJCC v8, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT04915508 is a Phase 2 study of Prostate Adenocarcinoma and Stage IVB Prostate Cancer AJCC v8 that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 102 participants, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04915508, a Phase 2 study of Prostate Adenocarcinoma and Stage IVB Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical prostatectomy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Hormone Therapy
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2021-06-23 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04915508
The ClinicalTrials.gov registry entry for NCT04915508 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (53% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT04915508 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04915508 about?
NCT04915508 is a clinical study titled "Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy". This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical prostatectomy. Stereotactic body radiation therapy uses special equipme...
What is the current status of trial NCT04915508?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2021-06-23. Estimated completion is 2027-08-01.
What conditions does trial NCT04915508 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8.
What interventions are being tested in trial NCT04915508?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Hormone Therapy (DRUG).
Who is sponsoring clinical trial NCT04915508?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04915508 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Prostate Adenocarcinoma
All registered trials for this condition
Stage IVB Prostate Cancer AJCC v8
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.